Menopausal vasomotor symptoms: A review of causes, effects and evidence-based treatment options

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 50, Issue 3, 2005, Pages 155-165

  Bachmann, Gloria A ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Flushing; Menopause; Vasomotor system

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA TOCOPHEROL; ANGELICA SINENSIS EXTRACT; CHINESE DRUG; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; CONJUGATED ESTROGEN; DAIDZEIN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; GENISTEIN; GLYCITEIN; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLDOPA; NORADRENALIN; NORETHISTERONE ACETATE; PAROXETINE; RED CLOVER EXTRACT; SEROTONIN; VENLAFAXINE; VERALIPRIDE;

CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DIET; DRUG CHOICE; DRUG EFFICACY; ESTROGEN METABOLISM; ESTROGEN THERAPY; HOT FLUSH; HUMAN; LIFESTYLE; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP; SYSTEMATIC REVIEW;

AGED; BODY TEMPERATURE REGULATION; ESTRADIOL; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; HYPOTHALAMUS; MEDICINE, HERBAL; MENOPAUSE; MIDDLE AGED; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 15344342735     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Stearns V, Ullmer L, Lopez JF, et al: Hot flushes. Lancet 2002;360:1851-1861
2. Kronenberg F: Hot flashes: Epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86
3. Kronenberg F: Hot flashes: Phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29: 319-336
4. Daly E, Gray A, Barlow D, et al: Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307: 836-840
5. Oldenhave A, Jaszmann LJB, Haspels AA, et al: Impact of climacteric on well-being: A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780
6. Joffe H, Hall JE, Soares CN, et al: Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398
7. Shanafelt TD, Barton DL, Adjei AA, et al: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218
8. Soules MR, Sherman S, Parrott E, et al: Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272
9. Fitzpatrick LA, Santen RJ: Hot flashes: The old and the new, what is really true? Mayo Clin Proc 2002;77:1155-1158
10. Thompson B, Hart SA, Durno D: Menopausal age and symptomatology in a general practice. J Biosoc Sci 1973;5: 71-82
11. Bachmarm GA: Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316
12. Taylor M: Psychological consequences of surgical menopause. J Reprod Med 2001;46:317-324
13. Gold EB, Sternfeld B, Kelsey JL, et al: Relation of demographic and lifestyle factors to symptoms in a multiracial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473
14. Fuh JL, Wang SJ, Lu SR, et al: The Kinmen women-health investigation (KIWI): A menopausal study of a population aged 40-54. Maturitas 2001;39:117-124
15. Whiteman MK, Staropoli CA, Benedict JC, et al: Risk factors for hot flashes in midlife women. J Womens Health 2003; 12:459-472
16. Erlik Y, Meldrum DR, Judd HL: Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 1982; 59:403-407
17. Wilbur J, Miller AM, Montgomery A, et al: Sociodemographic characteristics, biological factors, and symptom reporting in midlife women. Menopause 1998;5:43-51
18. Whiteman MK, Staropoli CA, Langenberg PW, et al: Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-272
19. Schwingl PJ, Hulka BS, Harlow SD: Risk factors for menopausal hot flashes. Obstet Gynecol 1994;84:29-34
20. Cohen FJ, Lu Y: Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000;34:65-7
21. Cummings SR, Eckert S, Krueger KA, et al: The effects of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. JAMA 1999281:2189-219
22. Kronenberg F, Barnard RM: Modulation of menopausal hot flashes by ambient temperature. J Therm Biol 1992;17:43-49
23. Randolph JF Jr, Sowers M, Gold EB, et al: Reproductive hormones in the early menopausal transition: Relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88:1516-1522
24. Meldrum DR, Shamonki IM, Frumar AM, et al: Elevations in skin temperature of the finger as an objective index of postmenopausal hot flashes: Standardization of the technique. Am J Obstet Gynecol 1979;135:713-717
25. Baker A, Simpson S, Dawson D: Sleep disruption and mood changes associated with menopause. J Psychosom Res 1997; 43:359-369
26. Hollander LE, Freeman EW, Sammel MD, et al: Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol 2001;98:391-397
27. Erlik Y, Tataryn IV, Meldrum DR, et al: Association of waking episodes with menopausal hot flushes. JAMA 1981; 245:1741-1744
28. Kravitz HM, Ganz PA, Bromberger J, et al: Sleep difficulty in women at midlife: A community survey of sleep and the menopausal transition. Menopause 2003;10:19-28
29. Young T, Rabago D, Zgierska A, et al: Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. Sleep 2003;26:667-672
30. Harlow BL, Cohen LS, Otto MW, et al: Prevalence and predictors of depressive symptoms in older premenopausal women: The Harvard Study of Moods and Cycles. Arch Gen Psychiatry 1999;56:418-424
31. Avis NE, Crawford S, Stellato R, et al: Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-249
32. Hlatky MA, Boothroyd D, Vittinghoff E, et al: Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: Results from the heart and estrogen/progestin replacement study (HERS) trial. JAMA 2002;287:591-597
33. Owens JF, Matthews KA, Everson SA: Cognitive function effects of suppressing ovarian hormones in young women. Menopause 2002;9:227-235
34. Groeneveld FP, Bareman FP, Barentsen R, et al: Vasomotor symptoms and well-being in the climacteric years. Maturitas 1996;23:293-299
35. Freedman RR: Core body temperature variation in symptomatic and asymptomatic postmenopausal women: Brief report. Menopause 2002;9:399-401
36. Freedman RR, Norton D, Woodward S, et al: Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358
37. Freedman RR, Krell W: Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70
38. Freedman RR, Blacker CM: Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002;77:487-490
39. Overlie I, Moen MH, Holte A, et al: Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002;41:69-77
40. Aksel S, Schomberg DW, Tyrey L, et al: Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976;126:165-169
41. Freeman EW, Sammel MD, Grisso JA, et al: Hot flashes in the late reproductive years: Risk factors for African American and Caucasian women. J Womens Health Gend Based Med 2001;10:67-76
42. Casper RF, Yen SS, Wilkes MM: Menopausal flushes: A neuroendocrine link with pulsatile luteinizing hormone secretion. Science 1979;205:823-825
43. Rosenberg J, Larsen SH: Hypothesis: Pathogenesis of post-menopausal hot flush. Med Hypotheses 1991;35:349-350
44. Freedman RR: Physiology of hot flashes. Am J Hum Biol 2001;13:453-464
45. Slopien R, Meczekalski B, Warenik-Szymankiewicz A: Relationship between climacteric symptoms and serum serotonin levels in postmenopausal women. Climacteric 2003; 6:53-57
46. Gonzales GF, Carrillo C: Blood serotonin levels in post-menopausal women: Effects of age and serum oestradiol levels, Maturitas 1993;17:23-29
47. Berendsen HH: The role of serotonin in hot flushes. Maturitas 2000;36:155-164
48. MacLennan A, Lester S, Moore V: Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Lib 2001;4:1-73
49. Utian WH, Shoupe D, Bachmann G, et al: Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079
50. Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. J Clin Oncol 2001; 19:4280-4290
51. Stevens RE, Hanford K, Wason S, et al: A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women. Int J Fertil 2000;45:264-272
52. Rebar RW, Trabal J, Mortola J: Low-dose esterified estrogens (0.3 mg/day): Long-term and short-term effects on menopausal symptoms and quality of life in post-menopausal women. Climacteric 2000;3:176-182
53. Notelovitz M, Mattox JH: Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000;7:310-317
54. Wiklund I, Karlberg J, Mattsson LA: Quality of life of post-menopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-830
55. Derman RJ, Dawood MY, Stone S: Quality of life during sequential hormone replacement therapy: A placebo-controlled study. Int J Fertil 1995;40:73-78
56. Baerug U, Winge T, Nordland G, et al: Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219-228
57. Speroff L, Symons J, Kempfert N, et al: The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (Femhrt®) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383-390
58. Shulman LP, Yankov V, Uhl K: Safety and efficacy of a continuous once-a-week 17β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: The results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195-207
59. Schiff I, Tulchinsky D, Cramer D, et al: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-1445
60. Loprinzi CL, Michalak JC, Quella SK, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347-352
61. Leonetti HB, Longo S, Anasti JN: Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228
62. Foster GV, Zacur HA, Rock JA: Hot flashes in post-menopausal women ameliorated by danazol. Fertil Steril 1985;43:401-404
63. Strickler R, Stovall DW, Merritt D, et al: Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: A placebo-controlled randomized trial. Obstet Gynecol 2000;96:359-365
64. Laufer LR, Erlik Y, Meldrum DR, et al: Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-586
65. Nagamani M, Kelver ME, Smith ER: Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561-565
66. Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158
67. Loprinzi CL, Sloan JA, Perez EA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583
68. Hammond MG, Hatley L, Talbert LM: A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab 1984;58:1158-1160
69. Stearns V, Beebe KL, Iyengar M, et al: Paroxetine controlled release in the treatment of menopausal hot flashes: A randomized controlled trial. JAMA 2003;289:2827-2834
70. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 2000;356:2059-2063
71. Melis GB, Gambacciani M, Cagnacci A, et al: Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988;72:688-692
72. Jacobson JS, Troxel AB, Evans J, et al: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-2745
73. Davis SR, Briganti EM, Chen RQ, et al: The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women: A randomised controlled trial. Med J Aust 2001;174:68-71
74. Hirata JD, Small R, Swiersz LM, et al: Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68:981-986
75. Tice JA, Ettinger B, Ensrud K, et al: Phytoestrogen supplements for the treatment of hot flashes: The Isoflavone Clover Extract (ICE) Study: A randomized controlled trial. JAMA 2003;290:207-214
76. Quella SK, Loprinzi CL, Barton DL, et al: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-1074
77. St. Germain A, Peterson CT, Robinson JG, et al: Isoflavonerich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001;8:17-26
78. Han KK, Scares JMJr, Haidar MA, et al: Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002;99:389-394
79. Upmalis DH, Lobo R, Bradley L, et al: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: A multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7:236-242
80. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al: A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213-1220
81. Van Patten CL, Olivotto IA, Chambers GK, et al: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. J Clin Oncol 2002;20:1449-1455
82. Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500
83. McNagny SE: Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-616
84. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
85. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 2003;289:3243-3253
86. Wassertheil-Smoller S, Hendrix S, Limacher M, et al: Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673-2684
87. Manson JE, Hsia J, Johnson KC, et al: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
88. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-2662
89. Keefe DL, Watson R, Naftolin F: Hormone replacement therapy may alleviate sleep apnea in menopausal women: A pilot study. Menopause 1999;6:196-200
90. Antonijevic IA, Stalla GK, Steiger A: Modulation of the sleep electroencephalogram by estrogen replacement in postmenopausal women. Am J Obstet Gynecol 2000;182: 277-282
91. 3H-imipramine binding sites in surgically menopausal women. Biol Psychiatry 1990;28:339-348
92. Sherwin BB: The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991;72:336-343
93. Casper RF, Dodin S, Reid RL, et al: The effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (Minestrin™), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139-147
94. Palinkas LA, Barrett-Connor E: Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol 1992;80:30-36
95. Greendale GA, Reboussin BA, Hogan P, et al: Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998;92:982-988
96. Gambacciani M, Ciaponi M, Cappagli B, et al: Effects of low-dose, continuous combined estradiol and norethisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 2003;44:157-163
97. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-1854
98. Grady D: Postmenopausal hormones: Therapy for symptoms only. N Engl J Med 2003;348:1835-1837
99. American College of Obstetricians and Gynecologists. Questions and answers on hormone therapy [news release]. http://www.acog.org/from_home/ publications/press_releases/nr08-30-02.cfm, accessed December 10, 2003
100. North American Menopause Society: Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 2003;10:6-12
101. Lindsay R, Gallagher JC, Kleerekoper M, et al: Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676
102. Speroff L, Whitcomb RW, Kempfert NJ, et al: Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstet Gynecol 1996;88:587-592
103. Gelfand MM: Role of androgens in surgical menopause. Am J Obstet Gynecol 1999;180:S325-S327
104. Voss S, Quail D, Dawson A, et al: A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: Effects on compliance and quality of life. Br J Obstet Gynecol 2002;109:874-885
105. Jones KP, Ravnikar V, Schiff I: A preliminary evaluation of the effect of lofexidine on vasomotor flushes in post-menopausal women: Maturitas 1985;7:135-139
106. Stearns V, Isaacs C, Rowland J, et al: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000; 11:17-22
107. Clayton AH, Pradko JF, Croft HA, et al: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
108. Thummala AR, Griggs J, Rosenblatt J: Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer (abstr). Proc of the American Society of Clinical Oncology 2002;21:362a
109. Loprinzi CL, Barton DL, Sloan JA, et al: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002;77: 1159-1163
110. Scambia G, Mango D, Signorile PG, et al: Clinical effects of a standardized soy extract in postmenopausal women: A pilot study. Menopause 2000;7:105-111